Get the Stockscreener App
4.25
1.62%
-0.07
Trisalus Life Sciences Inc stock is traded at $4.25, with a volume of 234.46K.
It is down -1.62% in the last 24 hours and up +4.42% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$4.32
Open:
$4.36
24h Volume:
234.46K
Relative Volume:
5.09
Market Cap:
$128.68M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.42%
1M Performance:
+4.42%
6M Performance:
-43.78%
1Y Performance:
+5.99%
1-Day Range:
$4.1484
$4.36
1-Week Range:
$4.06
$4.65
52-Week Range:
$3.61
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.25 | 128.68M | 15.33M | -40.19M | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
Trisalus Life Sciences Inc Stock (TLSI) Latest News
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock - Investing.com
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock By Investing.com - Investing.com UK
TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock By Investing.com - Investing.com Australia
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock - Investing.com India
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00 - Defense World
Canaccord cuts TriSalus shares target, keeps buy rating on Q3 report - Investing.com Canada
TriSalus Life Sciences (NASDAQ:TLSI) Given New $11.00 Price Target at Canaccord Genuity Group - MarketBeat
TriSalus Life Sciences Inc (TLSI) Quarterly 10-Q Report - Quartzy
MedTech Acquisition (OTCMKTS:MTACU) Files 8-K Report with SEC Announcement - Defense World
TriSalus Life Sciences Reports Strong Q3 Growth - TipRanks
TriSalus Reports Q3 2024 Financial Results and Provides Business Update - BioSpace
TriSalus Life Sciences Revenue Soars 42% in Q3, Expands into $375M Market | TLSI Stock News - StockTitan
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Previe - GuruFocus.com
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Q3 Earnings Estimate for TLSI Issued By Roth Capital - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Roth Capital to "Strong-Buy" Rating - MarketBeat
Roth/MKM starts TriSalus shares coverage with Buy rating, $11 target By Investing.com - Investing.com South Africa
Roth/MKM starts TriSalus shares coverage with Buy rating, $11 target - Investing.com Canada
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday - Benzinga
TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Roth Mkm - MarketBeat
Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav - Business Wire
Reviewing TriSalus Life Sciences (TLSI) and Its Peers - Defense World
Critical Comparison: CARGO Therapeutics (CRGX) and Its Rivals - Defense World
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment - BioSpace
TriSalus Life Sciences (TLSI) to Release Quarterly Earnings on Thursday - MarketBeat
TriSalus Life Sciences (TLSI) Set to Announce Earnings on Thursday - MarketBeat
TriSalus Life Sciences (TLSI) Set to Announce Quarterly Earnings on Thursday - Defense World
TriSalus Life Sciences® Inc. Launches TriNav® LV Infusion System and TriGuide? Guiding Catheters, Expanding Portfolio of PEDD? Devices for Improved Tumor Treatment - Marketscreener.com
TriSalus Life Sciences, Inc. Announces Resignation and Departure of Board Member and Chief Medical Officer - Defense World
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call - BioSpace
Northland Securities Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI) - Defense World
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA - openPR
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 21.3% in October - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Northland Capmk Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to "Strong-Buy" - MarketBeat
Northland initiates TriSalus shares with outperform, cites sales growth - Investing.com India
Northland initiates TriSalus shares with outperform, cites sales growth By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated by Analysts at Northland Securities - MarketBeat
ALUS presents the 2024 Dave Reid Award to François Allard - GlobeNewswire Inc.
Riad Salem Joins Scientific Advisory Board Of TriSalus Life Sciences - MPO-mag
Riad Salem Joins Scientific Advisory Board of TriSalus Life Sciences - MPO-mag
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - BioSpace
Interventional Approaches for Locally Advanced Pancreatic Cancer - HMP Global Learning Network
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 62.5% in September - MarketBeat
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):